Piedmont Heart Institute, Inc., Atlanta, GA
5
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 5 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Effect of MitraClip on Acute and Chronic Reverse Cardiac Remodeling Assessed by CMR: The MITRA-REVERSE Study
Role: collaborator
Outcomes of Surgically Ineligible Patients With Multivessel CAD
Role: collaborator
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
Role: collaborator
Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid rEgurgitation in Heart Failure With Reduced or Preserved Ejection Fraction
Role: collaborator
Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)
Role: collaborator
All 5 trials loaded